AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer
The OlympiAD monotherapy study paves the way for AstraZeneca's Lynparza in breast cancer, as well as other PARP inhibitors down the line, but the ASCO presentation raises questions about trial design and whether combinations are needed to boost efficacy.
